Fetal PLX-R18 cells have many similarities with hAMSC and, thus, these cells could be used in a preclinical model of graft versus host disease (GVHD), while PLX-PAD cells due to the high release of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and Angiopoietin have been tested in the animal model of hind limb ischemia [39,40]. This evidence concerns the gene VEGFA and graft versus host disease.